alexa Medicine Withdrawal and Recall: Needs Proper Evaluation
ISSN: 2167-1052

Advances in Pharmacoepidemiology and Drug Safety
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Letter to Editor

Medicine Withdrawal and Recall: Needs Proper Evaluation

Chetna Patel* and Shashank Deoghare
Department of Pharmacology, Government Medical College, Surat, Gujarat, India
*Corresponding Author : Chetna Patel
Associate Professor
Department of Pharmacology, GMC, Surat-395001, Gujarat, India
Tel: 9712077006
E-mail: [email protected]
Received October 01, 2012; Accepted October 22, 2012; Published October 24, 2012
Citation: Patel C, Deoghare S (2012) Medicine Withdrawal and Recall: Needs Proper Evaluation. Adv Pharmacoepidem Drug Safety 1:118. doi:10.4172/2167-1052.1000118
Copyright: © 2012 Patel C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Currently, withdrawal and recall of medicines become a hot topic of discussion. This issue does not follow a uniform pattern all over the world. Few medicines continue to remain in the market despite reported adverse effects. This is understandable because:
• They may be the only available options for a few sets of patients e.g. felbamate (anti-epileptic)
• Drug remains in the market until better options are available in terms of safety and efficacy e.g. terfenadine approved in 1985 was found to cause cardiac arrhythmias but it continued to be in the market till the arrival of newer analogue fexofenadine in 1997.
• Withdrawal may also become the last option to choose if all other risk management techniques fail as was observed in the case of heartburn treatment with cisapride

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version